Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.64 |
| ▸ | TACR1 | P25103 | 4/20 | 0.52 |
| ▸ | HTR6 | P50406 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18019795 | 1.00 | CHRNB4 (0.64) | CHRNB4CHRNA3TACR1HTR6POLB | |
| SCHEMBL13877462 | 1.00 | CHRNB4 (0.64) | CHRNB4CHRNA3TACR1HTR6POLB | |
| Hydrochloric Acid SCHEMBL3636932 | 0.98 | CHRNB4 (0.62) | CHRNB4CHRNA3TACR1HTR6POLB | |
| SCHEMBL18019873 | 0.95 | CHRNB4 (0.58) | CHRNB4CHRNA3TACR1HTR6POLB | |
| SCHEMBL18019869 | 0.95 | CHRNB4 (0.58) | CHRNB4CHRNA3TACR1HTR6POLB | |
| SCHEMBL17979768 | 0.95 | CHRNB4 (0.58) | CHRNB4CHRNA3TACR1HTR6POLB | |
| SCHEMBL11471256 | 0.94 | CHRNB4 (0.57) | CHRNB4CHRNA3TACR1HTR6POLB | |
| SCHEMBL23477672 | 0.87 | CHRNB4 (0.53) | CHRNB4CHRNA3TACR1HTR6 | |
| SCHEMBL30475084 | 0.87 | CHRNB4 (0.53) | CHRNB4CHRNA3TACR1HTR6 | |
| SCHEMBL8792312 | 0.85 | CHRNB4 (0.61) | CHRNB4CHRNA3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021068530-A1 | Z-TYPE SOLANONE, PREPARATION METHOD THEREFOR, AND USE | 云南中烟工业有限责任公司 | 2021-04-15 | — | — | WO | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | CHRNB4 4780/4885CHRNA3 4643/4885TACR1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.